CR rates in relapsed/refractory (R/R) aggressive B-NHL treated with the CD19-directed CAR T-cell product JCAR017 (TRANSCEND NHL 001).
Year: 2017
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: Massachusetts General Hospital, Memorial Sloan Kettering Cancer Center, Northwestern University, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, University of Nebraska Medical Center, Beth Israel Deaconess Medical Center, University of Alabama at Birmingham, The University of Texas MD Anderson Cancer Center, Juno Therapeutics (United States), City Of Hope National Medical Center
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2891294964